Replimune Group, Inc. (REPL)

Replimune’s first fiscal quarter of 2027 results missed consensus on earnings, with EPS of -$0.72 trailing the -$0.69 estimate by $0.03, based on preliminary figures reported August 14, 2026. Net income was a loss of about $69.8 million, improving ~20% year over year from a loss of about $86.7 million, alongside EPS that narrowed ~24% from -$0.95 a year ago. Operating income came in at a loss of roughly $68.2 million, and cash use remained elevated, with negative operating cash flow of about $75.7 million during the quarter as the clinical-stage biotech continued investing in its oncolytic immuno-gene therapy pipeline, including candidates RP1, RP2, and RP3. Looking ahead, next-period consensus calls for EPS of -$0.78 on revenue of $1.0 million.